Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Ligand Pharm (LGND)

Ligand Pharm (LGND)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Ligand (LGND) Down 12% Since Last Earnings Report: Can It Rebound?

Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

LGND : 86.11 (+0.63%)
AVEO : 8.23 (+1.11%)
Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that the Janssen Biotech, Inc. (Janssen) received conditional marketing authorization (CMA) from the European Commission for TECVAYLI ® (teclistamab)...

LGND : 86.11 (+0.63%)
AHPA : 10.20 (-0.05%)
Ligand Pharmaceuticals (LGND) Misses Q2 Earnings Estimates

Ligand (LGND) delivered earnings and revenue surprises of -37.04% and 44.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

LGND : 86.11 (+0.63%)
IDYA : 14.92 (+5.74%)
Ligand Reports Second Quarter 2022 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ended June 30, 2022 and provided an operating forecast and program updates. Ligand management...

LGND : 86.11 (+0.63%)
AHPA : 10.20 (-0.05%)
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Tops Revenue Estimates

Sangamo (SGMO) delivered earnings and revenue surprises of 17.14% and 26.24%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

SGMO : 4.90 (+0.62%)
LGND : 86.11 (+0.63%)
Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that effective August 1, 2022, Ligand’s Board of Directors approved the grant of non-qualified stock option awards to purchase an aggregate...

LGND : 86.11 (+0.63%)
Ligand to Report Second Quarter Financial Results on August 8

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report second quarter 2022 financial results after the close of the U.S. financial markets on Monday, August 8, 2022 and will hold a conference...

LGND : 86.11 (+0.63%)
Sever Your Ties With These 4 Toxic Stocks to Ward Off Losses

Just like picking up stocks with strong growth potential, pinpointing toxic stocks and abandoning them at the right time hold the key to protecting your portfolio from big losses.

LGND : 86.11 (+0.63%)
ORA : 86.20 (-0.17%)
ZLNDY : 9.7000 (+2.32%)
RADI : 9.42 (-4.37%)
Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (“Ligand” or “the Company”) announces the appointment of Jason Haas to the Company's Board of Directors. Mr. Haas brings more than 30 years...

LGND : 86.11 (+0.63%)
ASCO 2022: Surprising News in Cancer Research

The American Society of Clinical Oncology (ASCO) just finished up its annual meeting. We have some winners coming out of the conference.

ADPT : 7.12 (+3.94%)
LGND : 86.11 (+0.63%)
ACLX : 18.77 (-1.21%)

Barchart Exclusives

Unusual Options Activity: Selling Puts on These 3 Free Cash Flow Beauties
When selling put options, the conservative play is to consider quality companies with significant free cash flow generation. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar